Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-12-01T04:48:22.267Z Has data issue: false hasContentIssue false
  • English
  • Français

LAI versus oral antipsychotic treatment of schizophrenia: A 12-month prospective study on patient's attitude towards treatment and quality of life

Published online by Cambridge University Press:  23 March 2020

F. Pietrini ,
A. Ballerini ,
I. Burian ,
B. Campone ,
F. Chiarello ,
E. Ciampi ,
E. Corsi ,
N. Ferruccio ,
M. Moneglia  and
L. Poli
...Show all authors
A. Ballerini
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
I. Burian
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
B. Campone
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
F. Chiarello
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
E. Ciampi
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
E. Corsi
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
N. Ferruccio
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
M. Moneglia
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
L. Poli
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
A. Santangelo
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
S. Spitoni
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy
V. Ricca
Affiliation:
University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, section of Neuroscience, Florence, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

It is still a matter of debate whether LAI antipsychotics are able to significantly improve patient's attitude towards treatment.

Objective

The aim of this 12-month observational study was to investigate the impact of switching antipsychotic treatment from oral to LAI formulation on patient's attitude towards treatment and quality of life.

Methods

A total of 41 schizophrenic patients (25 males, mean age 42.10 ± 11.88 years) were recruited. Patients were expected not to need significant changes in concomitant treatments. All patients were under a stabilized therapy with a single oral antipsychotic (either olanzapine or paliperidone) and were switched to the equivalent maintenance regimen with the long-acting formulation of the same antipsychotic (olanzapine pamoate or paliperidone palmitate). Patients were assessed before the switch (T0), and after 6 (T1) and 12 months (T2) of LAI antipsychotic treatment by means of the YMRS, MADRS, PANSS, DAI-10 and SF-36.

Results

Our data evidenced an overall significant improvement of psychopathology, adherence and quality of life over the 12-month period (T0 vs. T2). In particular, while all of the measures significantly improved in the first semester (T0 vs. T1), only YMRS, positive PANSS and DAI-10 improved both in the first and in the second semester (T1 vs. T2), indicating an additional advantage of a prolonged LAI treatment on these clinical dimensions.

Conclusions

The switch from oral to long-acting antipsychotic treatment may provide considerable advantages in improving patient's attitude towards (and therefore adherence to) treatment. Part of this improvement could be related with a better efficacy on psychopathology and quality of life.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1181
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S583 - S584
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.